Insights

Brussels – March 27, 2026: The Legal 500 Europe, Middle East & Africa (EMEA) 2026 edition has recognized 13 practice areas and nine lawyers in Crowell & Moring’s Brussels office.

Chicago – June 11, 2025: Managing Intellectual Property has recognized 12 Crowell & Moring attorneys and four practices in its 2025 IP Stars guide. The guide, which is in its seventh edition, “brings together the world’s foremost law firm and corporate trademark experts, allowing the wider community to benefit from their insight, experience and perspectives.”

In our sixth alert in this EU Pharma Package Series, we provided an analysis of the history and interpretation issues for another highly debated topic: the “Bolar” exemption.

In our fifth alert in this EU Pharma Package Series, we provided an analysis of the background and ongoing legal debates regarding the concept of the global marketing authorization (GMA). We discussed in particular the missed opportunities in the Pharma Package to further codify and clarify the GMA, in view of its central role in determining the regulatory data protection (RDP) rights of a medicinal product.

In our fourth alert in this EU Pharma Package Series, we provided an analysis of the long-standing but increasingly debated issue of fiscal imports in the pharmaceutical supply chain and the EU’s evolving approach to this issue.

Crowell & Moring's Brussels office is featured in an article highlighting recent partner and senior counsel appointments, as well as an overview of the practice strengths of those individuals and the office as a whole. Brussels partner and office head, Kristof Roox, praises his colleagues, saying, "Jan-Diederik [Lindeman]'s promotion and the addition of Geert [Bogaert] reinforces the strength and breadth of experience that our Brussels office offers and demonstrates our continued investment" in staff appointments. The piece also focuses on the key aspects of the Brussels office, in particular the advising and litigating experience in EU and Belgian Law, intellectual property, pharmaceuticals, and life sciences.

In March 2024, after years of preparation, the Council of the European Union and the European Parliament reached a provisional agreement on a new regulation governing electronic health data. The regulation, known as the European Health Data Space, was first proposed in March 2022 and, when formally adopted, will apply to the primary use and secondary use of health data. This initiative is a key component of the broader EU data strategy and represents the first of nine sector– and domain–specific data spaces outlined in the European Commission’s 2020 communication on “A European strategy for data.”

An inescapable part of marketing your (non-food) products consists of managing the risks caused by defective and/or non-compliant products. To deal with the legal aspect of this risk, economic operators must take measures prior to putting their products on the market as well as once the product has been commercialized.

In collaboration with the IBJ

For any company marketing a product, managing the risks associated with defective or non-compliant products is a key part of the process, both prior to and during commercialization. In particular, you will first need to determine which regulatory framework applies by mapping out the context in which the product is to be made available. Then, once the product has been placed on the market, you will need to know how to handle the various issues that could arise in relation to safety or regulatory non-compliance.